Sinovac Biotechs COVID-19 Vaccine Shows Positive Early Results
Beijing-based Sinovac Biotech announced positive early data from a Phase I/II clinical trial of its COVID-19 vaccine, CoronaVac. The vaccine showed both favorable immunogenicity and safety.
According to the World Health Organization (WHO) there are more than 130 efforts globally to develop a vaccine against COVID-19. Generally, the ones furthest along are Moderna and the U.S National Institute of Allergy and Infectious Diseases (NAIAD) vaccine and the University of Oxford and AstraZeneca vaccine. Other companies moving ahead quickly include Johnson & Johnson, Sanofi, GlaxoSmithKline, Pfizer, BioNTech and Novavax.